Results

Total Results: 1,494 records

Showing results for "harms".

261. Abnormal-Uterine-Bleeding Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/abnormal-uterine-bleeding_executive.pdf
     March 01, 2013 - Key Question 2 What are the harms, including adverse events, associated with medical, behavioral, and … For KQ2, we did not rate of strength of evidence because a fully inclusive assessment of harms could … Using predefined criteria, we found 25 publications about harms that were eligible for inclusion. … This makes detection of harms challenging. … Across agents data are sparse to evaluate long-term improvements and risk of harms.

262. Chronic Kidney Disease Stages 1-3: Screening, Monitoring, and Treatment (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/kidney-disease-medicine_disposition-comments.pdf
     August 01, 2012 - There was evidence regarding the benefits or harms of screening with diabetes for macroalbuminuria … No direct data currently exist regarding benefits and harms of screening for or monitoring of CKD in … of non-diabetic adults for CKD improves clinical outcomes or increases harms. … the same as evidence that there are no harms associated with monitoring. 11. … be explicit about what types of harms these studies should be paying attention to.

263. Decision Modeling (ppt file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/medical-test-reviews-decision-modeling.ppt
     June 01, 2012 - Decision-analytic modeling to evaluate benefits and harms of medical tests: uses and limitations. … It also allows one to evaluate the tradeoff in benefits, harms, and costs of different test-and treat … of treatment in true-positive diagnoses and avoidance of harms of treatment in true-negative diagnoses … Decision-analytic modeling to evaluate benefits and harms of medical tests: uses and limitations. … Decision-analytic modeling to evaluate benefits and harms of medical tests: uses and limitations.

264. Decision Modeling (ppt file)
     effectivehealthcare.ahrq.gov/sites/default/files/medical-test-reviews-decision-modeling.ppt
     June 01, 2012 - Decision-analytic modeling to evaluate benefits and harms of medical tests: uses and limitations. … It also allows one to evaluate the tradeoff in benefits, harms, and costs of different test-and treat … of treatment in true-positive diagnoses and avoidance of harms of treatment in true-negative diagnoses … Decision-analytic modeling to evaluate benefits and harms of medical tests: uses and limitations. … Decision-analytic modeling to evaluate benefits and harms of medical tests: uses and limitations.

265. Telehealth for Women (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/telehealth-women-protocol.pdf
     June 21, 2021 - Harms (KQ1f and 2f) will also be addressed. … f) What are the harms of telehealth for women’s reproductive health? … f) What are the harms of telehealth for screening and interventions for interpersonal violence? … : o Health care avoidance o Psychological harms (e.g., anxiety, shame, guilt, stigma) IPV • Health … o Increased abuse or other forms of retaliation; and other reported harms of screening or identif

266. Kidney-Disease-Medicine Surveillance (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/kidney-disease-medicine_surveillance.pdf
     October 01, 2012 - January 2012 Surveillance Report: October 2012 Key Findings: - The conclusions for KQ2 (harms … of screening) and KQ4 (harms of monitoring), KQ6 (harms of treatment) are still considered valid … considered valid but additional studies are available - For KQ5 (benefits of treatment) and KQ6 (harms … CKD Screening Benefits and Harms 12 Conclusions From CER Executive Summary RAND Literature … screening of adults for CKD improves clinical outcomes or increases harms.

267. Evidence Report on the (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/dietary-supplements_research-protocol.pdf
     December 15, 2010 - Objectives The objectives of the current review are to examine the benefits and harms of concomitant … In response to the third specific comment, harms will not be measured but rather extracted as measured … Do the effect estimates of harms outcomes vary by age, ethnicity, gender, or health status? b. … (McHarm)31 for primary studies evaluating harms of treatment. … (from the McHarm checklist31): prespecified and valid definition of harms, mode of harms collection

268. Template for Reports Developed (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/menopause_research-protocol.pdf
     March 25, 2012 - What are the significant agent-specific harms/adverse effects of nonhormone therapies? … A point was raised about combining benefits and harms into a KQ. … RCTs = randomized controlled trials Key Question 2—Other Benefits/Harms Hormones We will use a … RCTs = randomized controlled trials Key Question 3—Nonhormone Other Benefits/Harms We will limit … What is the best evidence for determining harms of medical treatment? CMAJ 2006;174(5):645-6.

269. Comparative Effectiveness and Safety of Analgesics for Osteoarthritis—An Update of the 2006 Report. (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/osteoarthritis-pain-disposition-120516.pdf
     October 01, 2011 - This is because the focus of the review is on comparative benefits and harms. … Absolute rates are provided throughout the harms section when available (see GI and CV harms of celecoxib … , GI and CV harms of nonselective NSAIDs, GI and CV harms of aspirin). … Earlier section explains that RA trials included for assessment of harms only. … Reviewing general harms associated with PPIs was outside the scope of this review; we reported harms

270. Dietary-Supplements Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/dietary-supplements_executive.pdf
     April 01, 2012 - Evidence of both benefits and harms of adding a supplement to cardiovascular drugs has been reported … Clinical or intermediate harms outcomes (e.g., organ toxicity, serious adverse events, withdrawal due … Do the effect estimates of harms outcomes vary by age, ethnicity, gender, or health status? b. … Benefits and harms are measured as outcomes that may be clinical outcomes, their proxy surrogates, or … • Reported clinical or surrogate cardiovascular efficacy or harms, or pharmacokinetic outcomes, in

271. Topic-Brief2-Opioid-Withdrawal (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/topic-brief2-opioid-withdrawal.pdf
     April 01, 2021 - pain, effectiveness of interventions to mitigate risks of overdose or suicide, or how benefits and harms … • No systematic review evaluated benefits and harms of interventions to mitigate risks of harms ( … • No systematic review evaluated how benefits and harms of tapering support interventions varied … Incorporates issues around both clinical benefits and potential clinical harms Yes 2d. … Evidence on strategies to mitigate serious harms of tapering (overdose, suicide) is lacking.

272. Topic-Brief2-Opioid-Withdrawal (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/topic-brief2-opioid-withdrawal.pdf
     April 01, 2021 - pain, effectiveness of interventions to mitigate risks of overdose or suicide, or how benefits and harms … • No systematic review evaluated benefits and harms of interventions to mitigate risks of harms ( … • No systematic review evaluated how benefits and harms of tapering support interventions varied … Incorporates issues around both clinical benefits and potential clinical harms Yes 2d. … Evidence on strategies to mitigate serious harms of tapering (overdose, suicide) is lacking.

273. Migraine-Adults-Executive-130408 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/migraine-adults-executive-130408.pdf
     April 01, 2013 - What are the harms from preventive pharmacologic treatments when compared with placebo or no active … What are the harms from preventive pharmacologic treatments when compared with active pharmacologic … Risk of Bias Assessment We evaluated the risk of bias in individual studies for benefits and harms … KQ 2: What are the comparative harms from pharmacologic treatments for preventing migraine attacks in … We did not contact the authors requesting unreported benefits and harms.

274. Restless-Legs Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/restless-legs_executive.pdf
     November 01, 2012 - We assessed treatment-related harms and adherence. … What are the harms from RLS treatments? a. … What are the harms from RLS treatments? a. … What are the long-term harms from treatment? … Short-Term Harms We evaluated three measures of short-term treatment harms from randomized placebo controlled

275. Template for Draft Reports (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/long-term-care-adults-future_research.pdf
     July 01, 2013 - What are the harms to older adults as a result of HCBS and NHs? … while NH residents experienced higher rates of other harms. … What are the harms to older adults as a result of HCBS and NHs? … while NH residents experienced higher rates of other harms. … What are the harms to older adults as a result of HCBS and NHs?

276. Treatments for Adults with Schizophrenia: A Systematic Review (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/schizophrenia-adult_research-protocol.pdf
     September 23, 2016 - What are the benefits and harms of psychosocial and other non-pharmacological treatments for adults … How do the benefits and harms of nonpharmacological treatments for adults with schizophrenia vary by … of antipsychotic drugs, populations can be mixed-diagnoses, as the harms are not population-specific … of any included intervention, systematic reviews of observational studies to evaluate harms will be … o For studies specifically on harms of antipsychotic drugs, populations can be mixed-diagnoses, as the

277. Management of Acute Diverticulitis Topic Nomination Disposition (pdf file)
     effectivehealthcare.ahrq.gov/system/files/docs/acute-diverticulitis-topic-nomination.pdf
     August 13, 2018 - Do the effectiveness/harms vary by patient characteristics or presentation of illness? … Do the benefits and harms vary by patient characteristics or presentation of illness? … Do the benefits and harms vary by patient characteristics or presentation/course of illness? … Do the benefits and harms vary by patient characteristics or presentation/course of illness? … addresses both benefits and potential harms. 2e.

278. Layout 1 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/ace-inhibitor-arb-update_executive.pdf
     June 01, 2011 - This review summarizes the evidence on the comparative long-term benefits and harms of ACEIs, ARBs, and … strength of evidence and brief conclusions from this review of the comparative long-term benefits and harms … Summary of evidence on comparative long-term benefits and harms of ACEIs, ARBs, and direct renin inhibitors … Summary of evidence on comparative long-term benefits and harms of ACEIs, ARBs, and direct renin inhibitors … (4) The potential to gain insight on the comparative benefits and harms of ACEIs, ARBs, and direct

279. Smoking-Pregnancy-Infants Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/smoking-pregnancy-infants_executive.pdf
     February 01, 2014 - Key Question 3: What are the harms of interventions intended to achieve or maintain smoking cessation … Data on harms or adverse effects of included interventions are captured in Key Question 3. … Intervention Harms for Pregnant and Postpartum Women We identified four studies that reported harms … None of the studies that evaluated relapse prevention interventions reported harms data. … Harms data were rarely reported. References 1. Centers for Disease Control and Prevention.

280. Comparative Effectiveness Reiew 243_Prehospital Airway Management: A Systematic Review (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/cer-243-prehospital-airway-management-evidence-summary_0.pdf
     June 01, 2021 - Summary Main Points • Four Key Questions addressed the comparative benefits and harms … endotracheal intubation [ETI]); Key Question 3 – SGA versus ETI; and Key Question 4 – how the benefits and harms … arrest c Success was qualitatively synthesized for KQ1 and 2; results available in full report d Harms … were qualitatively synthesized; meta-analysis not possible as harms are different Also included in